Synthetic storm: The Alarming Rise of THC, CBD, and SCs Vaping Among US Adolescents

Research has revealed that adolescent vaping of current delta-9-tetrahydrocannabinol (THC), cannabidiol (CBD), and synthetic cannabinoids (SCs) has increased between 2021 and 2023. This trend is particularly alarming given the lack of understanding about the long-term health effects of cannabis vaping.

The study, published in the American Journal of Preventive Medicine, analyzed national trends of adolescent cannabis vaping from the National Youth Tobacco Survey for 2021, 2022, and 2023, comprising a total of 69,899 US middle and high school students (aged 11 to 18 years).

Lead investigator Jack Chung, BApsych (Hons), National Centre for Youth Substance Use Research, and School of Psychology, Faculty of Health and Behavioural Sciences, The University of Queensland, says, “We found a significant increase in adolescent vaping of THC, CBD, and SCs from 2021 to 2023. THC vaping peaked in 2022 while the use of SCs continued to increase. Adolescents increasingly expressed uncertainty about the substances they were vaping; for example, uncertain respondents answering ‘don’t know’ if they have vaped SCs tripled across the years.”

In 2023, it is estimated that 7.4% (or 2.55 million) of US adolescents were currently vaping THC, while 2.9% (or 999,000) were vaping CBD, and 1.8% (or 620,000) were vaping SCs.

Individuals who vape cannabis exhibit more mental health symptoms compared to those who use traditional combustion methods of dry herbs and flowers. SCs are typically lab-synthesized to mimic the effects of naturally occurring cannabinoids and often bind more strongly to brain receptors, leading to more intense and unpredictable health consequences.

Mr. Chung remarks, “One of the most unexpected findings from our study was the continued rise in adolescent use of SCs. This trend is particularly alarming given that these substances are often accessed through unregulated, illicit markets, where there are no safety standards or quality controls.”

Co-investigator Gary C.K. Chan, PhD, National Centre for Youth Substance Use Research, Faculty of Health and Behavioural Sciences, The University of Queensland, adds, “We still know very little about the long-term health effects of cannabis vaping, which makes it even more important to understand what’s in your vape.”

This study is one of the first to track national adolescent vaping prevalence of THC, CBD, and SCs independently, given that most recent studies categorized various cannabinoids vaping under the umbrella term “cannabis vaping,” despite their vastly different psychological and health effects.

Mr. Chung concludes, “Experimentation with substance use among teenagers is often driven by peer influence, curiosity, and a desire for social acceptance. This age group may also be increasingly exposed to cannabis-related marketing on social media platforms such as TikTok and YouTube, as well as social media influencers and celebrities.”

The scientific community has made significant strides in recent years towards developing innovative methods for producing and analyzing complex molecules. In an exciting breakthrough, researchers from Ca’ Foscari University of Venice, along with international collaborators, have successfully harnessed the potential of brewer’s yeast to create miniature factories that produce macrocyclic peptides – promising drugs with high therapeutic value.

Macrocyclic peptides are a class of molecules that offer precision targeting, stability, and safety, making them an attractive alternative to traditional drugs. However, conventional methods for discovering and testing these peptides have been complex, slow, and environmentally unfriendly. To overcome these limitations, the researchers engineered brewer’s yeast cells to individually produce different macrocyclic peptides.

Each yeast cell acts as a tiny factory that lights up when producing the compound, allowing scientists to swiftly identify promising peptides. Using advanced fluorescence-based techniques, the team screened billions of micro-factories in just a few hours – a process significantly faster and more ecofriendly than existing methods.

Lead author Sara Linciano explained the innovative approach: “We manipulated yeast cells so that each one functions as a ‘micro-factory’ that becomes fluorescent when producing a specific compound. This allowed us to analyze 100 million different peptides rapidly and effectively.”

The study’s co-leader, Ylenia Mazzocato, highlighted the sustainability of their approach: “By exploiting the natural machinery of yeast, we produce peptide molecules that are biocompatible and biodegradable, making them safe for health and the environment – a truly ‘green pharma’ approach.”

The researchers also demonstrated the excellent binding properties of these peptides using X-ray crystallography. This new method offers significant advancements for drug discovery, especially for challenging targets that conventional drugs cannot easily address.

As Alessandro Angelini, associate professor and study coordinator, emphasized: “We are pushing the boundaries of this technology to create macrocyclic peptides that can deliver advanced therapies directly to specific cells, potentially revolutionising treatments. This could greatly benefit patient health and have substantial scientific and economic impacts.”

This work was part of the National Recovery and Resilience Plan (PNRR), supported by the European Union’s Next Generation EU initiative. The team involved multidisciplinary experts from Ca’ Foscari University of Venice, Kyoto Institute of Technology, Chinese Academy of Sciences, University of Padova, and École Polytechnique Fédérale de Lausanne.

Part of this technology has already been patented by Ca’ Foscari and was recently acquired by the startup Arzanya S.r.l. As Angelini concluded: “Seeing our technology gain international recognition makes me proud. I hope Arzanya S.r.l. can provide our talented young researchers with the opportunity to pursue their passions here in Italy, without necessarily needing to move abroad.”

The COVID-19 pandemic has taken a devastating toll on global health, with severe complications and immune-driven tissue damage being major concerns. A recent study published in Cell Reports reveals that the SARS-CoV-2 nucleocapsid protein can spread from infected to uninfected cells, triggering an immune response that mistakenly targets healthy cells. Researchers at the Hebrew University of Jerusalem have identified how this viral protein binds to cell surfaces and found a common anticoagulant, enoxaparin, can block this harmful interaction.

The study, led by PhD students Jamal Fahoum and Maria Billan from the Faculty of Medicine at the Hebrew University of Jerusalem, uncovers a surprising mechanism by which the SARS-CoV-2 virus causes immune-mediated tissue damage. The researchers used laboratory-grown cells, sophisticated imaging techniques, and samples from COVID-19 patients to understand how a specific viral protein attaches to healthy cells.

They discovered that this protein sticks to certain sugar-like molecules found on the surface of many cells, called Heparan Sulfate proteoglycans. When this happens, clumps of the viral protein form on these healthy cells. The immune system then mistakenly attacks these clumps using antibodies, which sets off a chain reaction that might damage both infected and healthy cells in the infected organism.

However, the researchers found that the drug enoxaparin can block the viral protein from sticking to healthy cells by taking over the spots the protein would normally bind to. In both lab experiments and when samples obtained from patients were tested in the lab, enoxaparin stopped the protein from attaching to cells and helped prevent the immune system from mistakenly attacking them.

This research sheds light on the mechanisms behind severe COVID-19 complications and immune-driven tissue damage. The findings open the door to new strategies for preventing immune-driven damage in COVID-19 and possibly other viral infections. Moreover, this study highlights the importance of collaborative efforts between clinicians and researchers in understanding the complexities of viral infections.

The authors dedicate this article to the memory of the late Prof. Hervé (Hillel) Bercovier, a gifted microbiologist, an inspiring scientist, and a great mentor. This research was supported by several research funds, including major contributions from The Edmond and Benjamin de Rothschild Foundation and The Israel Science Foundation of the Israel Academy of Science and Humanities.